A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer

Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with ablation (cryoablation or histotripsy) OR pembrolizumab alone. Participants will be randomly assigned.

Trial Details

NCT ID
NCT06246968
Phase
PHASE1
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • Pembrolizumab
  • Cryoablation
Locations (sample)
  • Basking Ridge, New Jersey, United States|40.70621,-74.54932
  • Middletown, New Jersey, United States|40.39428,-74.11709
  • Montvale, New Jersey, United States|41.04676,-74.02292
  • Commack, New York, United States|40.84288,-73.29289
  • Harrison, New York, United States|40.96899,-73.71263

Key Eligibility Criteria

  • Patients ≥ 18 years of age
  • Confirmed histologic diagnosis of metastatic TNBC or locally advanced inoperable TNBC
  • 1 site amenable cryoablation of at least 1.5 cm in size as determined by an Interventional Radiologist. Eligible cryoablation sites include (but no…
  • Physically fit (clinically eligible) to undergo ablation as per usual clinical practice

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →